SAM
CLDX icon

Smartleaf Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Smartleaf Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.1K Hold
511
– – ﹤0.01% 2033
2026
Q1 		$15.1K Buy
511
+220
+76% +$6K ﹤0.01% 2112
2025
Q4 		$7.69K Buy
291
+239
+460% +$6.29K ﹤0.01% 2506
2025
Q3 		$1.36K Buy
52
+45
+643% +$1.04K ﹤0.01% 2693
2025
Q2 		$142 Buy
+7
New +$136 ﹤0.01% 2682
2025
Q1 		– Sell
-303
Closed -$7.61K – 2885
2024
Q4 		$7.61K Buy
303
+113
+59% +$3.07K ﹤0.01% 2094
2024
Q3 		$6.31K Buy
190
+162
+579% +$6.17K ﹤0.01% 2009
2024
Q2 		$1.05K Buy
+28
New +$1.06K ﹤0.01% 2407

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Smartleaf Asset Management's CLDX Position: Q2 2026 in Review

Smartleaf Asset Management held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 511 shares worth $19.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2033.

Smartleaf Asset Management first reported a position in CLDX in Q2 2024 and has held it in 8 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Smartleaf Asset Management held 511 shares of Celldex Therapeutics worth $19.1K as of Q2 2026.
  • Smartleaf Asset Management left its Celldex Therapeutics share count unchanged in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2033 holding.
  • Smartleaf Asset Management first reported a position in Celldex Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.